Uterine Lavage Identifies Cancer Mutations and Increased TP53 Somatic Mutation Burden in Individuals with Ovarian Cancer

Author:

Ghezelayagh Talayeh S.12,Kohrn Brendan F.2ORCID,Fredrickson Jeanne2,Manhardt Enna1,Radke Marc R.1ORCID,Katz Ronit1ORCID,Gray Heidi J.1,Urban Renata R.1,Pennington Kathryn P.1,Liao John B.1,Doll Kemi M.1,Simons Elise J.1,Burzawa Jennifer K.1,Goff Barbara A.1ORCID,Speiser Paul3,Swisher Elizabeth M.1ORCID,Norquist Barbara M.1ORCID,Risques Rosa Ana2ORCID

Affiliation:

1. 1Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington.

2. 2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington.

3. 3Medical University of Vienna, Vienna, Austria.

Abstract

Current screening methods for ovarian cancer have failed to demonstrate a significant reduction in mortality. Uterine lavage combined with TP53 ultradeep sequencing for the detection of disseminated ovarian cancer cells has emerged as a promising tool, but this approach has not been tested for early-stage disease or non-serous histologies. In addition, lavages carry multiple background mutations, the significance of which is poorly understood. Uterine lavage was collected preoperatively in 34 patients undergoing surgery for suspected ovarian malignancy including 14 patients with benign disease and 20 patients with ovarian cancer [6 non-serous and 14 high-grade serous-like (serous)]. Ultradeep duplex sequencing (∼3,000×) with a panel of common ovarian cancer genes identified the tumor mutation in 33% of non-serous (all early stage) and 79% of serous cancers (including four early stage). In addition, all lavages carried multiple somatic mutations (average of 25 mutations per lavage), more than half of which corresponded to common cancer driver mutations. Driver mutations in KRAS, PIK3CA, PTEN, PPP2R1A, and ARID1A presented as larger clones than non-driver mutations and with similar frequency in lavages from patients with and without ovarian cancer, indicating prevalent somatic evolution in all patients. Driver TP53 mutations, however, presented as significantly larger clones and with higher frequency in lavages from individuals with ovarian cancer, suggesting that TP53-specific clonal expansions are linked to ovarian cancer development. Our results demonstrate that lavages capture cancer cells, even from early-stage cancers, as well as other clonal expansions and support further exploration of TP53 mutation burden as a potential ovarian cancer risk factor. Significance: Cancer driver mutations are found in uterine lavage DNA in all individuals, but driver TP53 mutations presented as significantly larger clones and with higher frequency in lavages from individuals with ovarian cancer. This suggests that TP53-specific clonal expansion plays a role in tumorigenesis and presents opportunities for early detection.

Funder

HHS | National Institutes of Health

Rivkin Center for Ovarian Cancer

HHS | NIH | National Cancer Institute

Minnesota Ovarian Cancer Alliance

Publisher

American Association for Cancer Research (AACR)

Reference41 articles.

1. Cancer statistics, 2020;Siegel;CA Cancer J Clin,2020

2. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

3. Surveillance, Epidemiology, and End Results (SEER) Program Populations (1969–2020) (www.seer.cancer.gov/popdata), National Cancer Institute, DCCPS, Surveillance Research Program;Ovary SEER 5-Year Relative Survival Rates, 2012–2018,2022

4. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial;Buys;JAMA,2011

5. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial;Jacobs;Lancet,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3